London - Riverside Research Ethics Committee
Level 3 Block B
Whitefriars
Lewins Mead
Bristol
BS1 2NT

Telephone: 02071048044

Please note: This is the favourable opinion of the REC only and does not allow you to start your study at NHS sites in England until you receive HRA Approval

07 January 2018

Mr James Larkin
Royal Marsden Hospital
Downs Road
Sutton
SM2 5PT

Dear Mr Larkin

Study title:	**Renal Adjuvant MultiPle Arm Randomised Trial (RAMPART): An international investigator-led phase III multi-arm multi-stage randomised controlled platform trial of adjuvant therapy in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse**
REC reference:	**17/LO/1875**
Protocol number:	**RE06**
EudraCT number:	**2017-002329-39**
IRAS project ID:	**219487**

Thank you for your letter of 22nd December 2017, responding to the Committee's request for further information on the above research and submitting revised documentation.

The further information has been considered on behalf of the Committee by the Chair

We plan to publish your research summary wording for the above study on the HRA website, together with your contact details. Publication will be no earlier than three months from the date of this opinion letter. Should you wish to provide a substitute contact point, require further

information, or wish to make a request to postpone publication, please contact hra.studyregistration@nhs.net outlining the reasons for your request.

Confirmation of ethical opinion

On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above research on the basis described in the application form, protocol and supporting documentation as revised, subject to the conditions specified below.

Conditions of the favourable opinion

The REC favourable opinion is subject to the following conditions being met prior to the start of the study.

Management permission must be obtained from each host organisation prior to the start of the study at the site concerned.

Management permission should be sought from all NHS organisations involved in the study in accordance with NHS research governance arrangements. Each NHS organisation must confirm through the signing of agreements and/or other documents that it has given permission for the research to proceed (except where explicitly specified otherwise).

Guidance on applying for NHS permission for research is available in the Integrated Research Application System, www.hra.nhs.uk or at http://www.rdforum.nhs.uk.

Where a NHS organisation's role in the study is limited to identifying and referring potential participants to research sites ("participant identification centre"), guidance should be sought from the R&D office on the information it requires to give permission for this activity.

For non-NHS sites, site management permission should be obtained in accordance with the procedures of the relevant host organisation.

Sponsors are not required to notify the Committee of management permissions from host organisations

Registration of Clinical Trials

All clinical trials (defined as the first four categories on the IRAS filter page) must be registered on a publically accessible database within 6 weeks of recruitment of the first participant (for medical device studies, within the timeline determined by the current registration and publication trees).

There is no requirement to separately notify the REC but you should do so at the earliest opportunity e.g. when submitting an amendment. We will audit the registration details as part of the annual progress reporting process.

To ensure transparency in research, we strongly recommend that all research is registered but for non-clinical trials this is not currently mandatory.

If a sponsor wishes to request a deferral for study registration within the required timeframe, they should contact hra.studyregistration@nhs.net. The expectation is that all clinical trials will

be registered, however, in exceptional circumstances non registration may be permissible with prior agreement from the HRA. Guidance on where to register is provided on the HRA website.

Clinical trial authorisation must be obtained from the Medicines and Healthcare products Regulatory Agency (MHRA).

The sponsor is asked to provide the Committee with a copy of the notice from the MHRA, either confirming clinical trial authorisation or giving grounds for non-acceptance, as soon as this is available.

It is the responsibility of the sponsor to ensure that all the conditions are complied with before the start of the study or its initiation at a particular site (as applicable).

Ethical review of research sites

NHS sites

The favourable opinion applies to all NHS sites listed in the application, subject to management permission being obtained from the NHS/HSC R&D office prior to the start of the study (see "Conditions of the favourable opinion" below).

Non-NHS sites

The Committee has not yet completed any site-specific assessment (SSA) for the non-NHS research site(s) taking part in this study. The favourable opinion does not therefore apply to any non-NHS site at present. We will write to you again as soon as an SSA application(s) has been reviewed. In the meantime no study procedures should be initiated at non-NHS sites.

Approved documents

The final list of documents reviewed and approved by the Committee is as follows:

Document	*Version*	*Date*
Confirmation of Clinical Trial Authorisation from MHRA and relevant correspondence [Clinical Trials Authorisation]	1.0	24 November 2017
Confirmation of Clinical Trial Authorisation from MHRA and relevant correspondence [Re-Submission Cover Letter]	1.0	22 November 2017
Confirmation of Clinical Trial Authorisation from MHRA and relevant correspondence [Grounds for Non-Acceptance Letter]	1.0	08 November 2017
Confirmation of Clinical Trial Authorisation from MHRA and relevant correspondence [Initial Submission Cover Letter]	1.0	13 October 2017
Covering letter on headed paper [Cover Letter]		12 October 2017
Covering letter on headed paper [HRA Response Cover Letter]	1.0	15 December 2017
Details of any Data Monitoring Committee [IDMC Letter]		02 October 2017
Evidence of Sponsor insurance or indemnity (non NHS Sponsors only) [Insurance]		24 July 2017
GP/consultant information sheets or letters [GP Letter]	1.0	03 October 2017
Investigator's brochure / IMP Dossier [Durvalumab IB]	11.0	28 April 2017
Investigator's brochure / IMP Dossier [Tremelimumab IB]	6.0	07 June 2016
IRAS Application Form [IRAS_Form_13102017]		13 October 2017

IRAS Checklist XML [Checklist_15122017]		15 December 2017
Letter from funder [AZ Confirmation of funding]		29 September 2016
Letter from sponsor [Confirmation of sponsorship]		02 October 2017
Letter from statistician [Letter from Statistician]		04 October 2017
Other [RAMPART_Cover_Letter_MHRA_GNA_Response_2017-11-22]		22 November 2017
Other [CTA_2017-11-24]		24 November 2017
Participant consent form [Participant Consent Form]	1.0	03 October 2017
Participant consent form [Partner Consent Form]	1.0	03 October 2017
Participant information sheet (PIS) [Participant Information Sheet (clean)]	1.0	15 December 2017
Participant information sheet (PIS) [Participant Information Sheet (tracked changes)]	1.0	15 December 2017
Participant information sheet (PIS) [Pregnant Partner Information Sheet]	1.0	15 December 2017
Referee's report or other scientific critique report [RAMPART Funding and Scientific peer-review]		08 May 2017
Research protocol or project proposal [Protocol]	1.0	22 November 2017
Research protocol or project proposal [RAMPART Protocol_v1.0_2017-11-22_trackedchanges]	1.0	22 November 2017
Summary CV for Chief Investigator (CI) [CI CV]		03 October 2017
Summary, synopsis or diagram (flowchart) of protocol in non technical language [RAMPART Lay Summary]	1.0	03 October 2017
Validated questionnaire [EQ-5D]	1.0	12 October 2017
Validated questionnaire [QLQ-C30]	1.0	12 October 2017

Statement of compliance

The Committee is constituted in accordance with the Governance Arrangements for Research Ethics Committees and complies fully with the Standard Operating Procedures for Research Ethics Committees in the UK.

After ethical review

Reporting requirements

The attached document *"After ethical review – guidance for researchers"* gives detailed guidance on reporting requirements for studies with a favourable opinion, including:

- Notifying substantial amendments
- Adding new sites and investigators
- Notification of serious breaches of the protocol
- Progress and safety reports
- Notifying the end of the study

The HRA website also provides guidance on these topics, which is updated in the light of changes in reporting requirements or procedures.

User Feedback

The Health Research Authority is continually striving to provide a high quality service to all applicants and sponsors. You are invited to give your view of the service you have received and the application procedure. If you wish to make your views known please use the feedback form available on the HRA website:
http://www.hra.nhs.uk/about-the-hra/governance/quality-assurance/

HRA Training

We are pleased to welcome researchers and R&D staff at our training days – see details at http://www.hra.nhs.uk/hra-training/

17/LO/1875	**Please quote this number on all correspondence**

With the Committee's best wishes for the success of this project.

Yours sincerely

Pp

REC Manager

Dr Margaret Jones
Chair

Email: nrescommittee.london-riverside@nhs.net

Enclosures: "After ethical review – guidance for researchers"

Copy to: *RAMPART Trial Management Team*
Ms Jane Lawrence, The Royal Marsden NHS Trust